載入中
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
前收盤價
US$5.34
+US$0.03 · +0.56%
盤中時間採用ET。市場資料可能有所延遲。
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
日內區間
目前US$5.34
52週區間
目前US$5.34
盤中時間採用ET。市場資料可能有所延遲。
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
日內區間
目前US$5.34
52週區間
目前US$5.34
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 218.6萬 USD | 394.5萬 USD | 1552.9萬 USD | 1390.7萬 USD | 435.9萬 USD |
| 銷貨成本 | 93萬 USD | — | — | — | — |
| 毛利 | 125.6萬 USD | 394.5萬 USD | 1552.9萬 USD | 1390.7萬 USD | 435.9萬 USD |
| 研究與開發 | 6945.3萬 USD | 7026.9萬 USD | 7304萬 USD | 8507.7萬 USD | 1.04億 USD |
| 銷售、一般及管理費用 | 2071.8萬 USD | 2283萬 USD | 3061.6萬 USD | 2641萬 USD | 2852.7萬 USD |
| 營業費用 | 8924.1萬 USD | 9309.9萬 USD | 1.04億 USD | 1.11億 USD | 1.33億 USD |
| 利息收入 | 216.4萬 USD | 167萬 USD | 124.3萬 USD | 164萬 USD | 13.2萬 USD |
| 折舊和攤銷 | 93萬 USD | 262.2萬 USD | 306.9萬 USD | 367.5萬 USD | 377.8萬 USD |
| 營業利益 | −8798.5萬 USD | −8915.4萬 USD | −8812.7萬 USD | −9758萬 USD | −1.28億 USD |
| 淨利 | −2419.3萬 USD | −1.31億 USD | −8767.9萬 USD | −9604.6萬 USD | −1.28億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$20.00
上漲空間 274.53%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年8月19日 | 1:25 | — | — |
已生效 2024年8月19日
1:25
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI75.46萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF27.41萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC8.26萬0.01%13.17億 USD0.60%US$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC4.42萬0.00%75.58億 USD0.43%US$57.813+0.20%
Dimensional - US Small Cap ETFDFAS3.39萬0.00%338.69億 USD0.31%US$78.35+0.32%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.11萬0.00%61.81億 USD0.26%US$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC9850.050.00%885.96億 USD0.21%US$45.33+0.49%
Avantis U.S. Small Cap Equity ETFAVSC7577.37—30.82億 USD0.25%US$69.98+0.03%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
